Justin P.O. Lindemann

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · Journal of Clinical Oncology · 2010 · 630 citations · Full text

AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue et al. · Journal of Clinical Oncology · 2017 · 315 citations · Full text

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

J.F.R. Robertson, Antonio Llombart‐Cussac, Janusz Rolski et al. · Journal of Clinical Oncology · 2009 · 311 citations

FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer

Jonas Bergh, Per‐Ebbe Jönsson, Elisabet Lidbrink et al. · Journal of Clinical Oncology · 2012 · 264 citations

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

J.F.R. Robertson, Justin P.O. Lindemann, Antonio Llombart‐Cussac et al. · Breast Cancer Research and Treatment · 2012 · 171 citations

Advanced Breast Cancer, Breast Oncology, Medicine +8